Monica Sikka, MD

Monica Sikka, MD

Monica Sikka, MD
Associate Professor of Medicine
PVAMC Outpatient Parenteral Antimicrobial Therapy (OPAT) Medical Director
Division of Infectious Diseases, PVAMC & OHSU

Degrees

M.D., University of Tennessee College of Medicine, Memphis, TN, 2003

Residency

Internal Medicine, University of Illinois at Chicago, 2006

Fellowship

Infectious Diseases, Rush University Medical Center, Chicago, IL, 2009

Board certification

American Board of Internal Medicine, 2006, 2016
American Board of Internal Medicine, Infectious Diseases, 2009, 2019

Biography

Dr. Sikka was born and raised in East Tennessee. She received her medical degree from the University of Tennessee College of Medicine and then moved to Chicago for the rest of her medical training. She completed her Internal Medicine residency at the University of Illinois at Chicago and her Infectious Diseases fellowship at Rush University Medical Center. She is board certified in both Internal Medicine and Infectious Diseases.

Dr. Sikka moved to Portland from the Midwest in 2017. She currently serves as the medical director of the Outpatient Parenteral Antimicrobial Therapy (OPAT) program at the Portland VA Medical Center and practices hospital epidemiology. She has a special interest in treatment of infections in patients with substance use disorder, caring for HIV patients and helping to reduce healthcare associated infections. She enjoys teaching medical students, residents, and fellows.

In her spare time, Dr. Sikka enjoys traveling, baking, finding great food, and being outdoors.

Selected publications

  1. Jeffrey Capizzi, Judith Leahy, Haven Wheelock, Jonathan Garcia, Luke Strnad, Monica Sikka, Honora Englander, Ann Thomas, Todd Korthuis, Timothy Menza. Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008-2018. PLOS ONE. Published on-line Nov 9, 2020. https://doi.org/10.1371/journal.pone.0242165
  2. Lauren Fontana, Holly Villamagna, Monica Sikka, Jessina McGregor. Understanding Viral Shedding of SARS-CoV-2: Review of current literature. Infection Control & Hospital Epidemiology. Oct 2020, 1-35. https://doi.org/10.1017/ice.2020.1273
  3. Hurley H, Sikka M, Jenkins T, Cari E, Thornton A. Outpatient Antimicrobial Treatment for People Who Inject Drugs. Infectious Disease Clinics of North America, 525-538, 34, 3, Sept 2020. https://doi.org/10.1016/j.idc.2020.06.009
  4. Hirofumi Yoshido, Claire Groth, Lauren Fontana, North Noelck, Monica Sikka. Chest pain and Eosinophilia in a Returning Traveler. Accepted for publication in The American Journal of Medicine for February 2021 issue. Available on-line in pre-print Aug 15, 2020. https://doi.org/10.1016/j.amjmed.2020.07.019
  5. Streifel, AC, Sikka MK. The Urgent Need for Medicare Reimbursement for Home Infusion Antibiotics amidst a Pandemic. Clinical Infectious Diseases. May 28,2020.ciaa658, https://doi.org/10.1093/cid/ciaa658
  6. Oda G, Winters MA, Pacheco SM, Sikka MK, Bleasdale SC, Dunn B, Boswell E, Winters B, Bumsted A, Frisch J, Holodniy M. Clusters of nontuberculous mycobacteria linked to water sources at three Veterans Affairs medical centers. Infection Control & Hospital Epidemiology, 1-11. doi:10.1017/ice.2019.342. 2019 Dec 11.
  7. Streifel AC, Sikka MK, Bowen CD, Lewis JS 2nd; Dalbavancin use in an academic medical center and associated cost-savings. Int J Antimicrob Agents. 2019 Aug 6. Pii:S0924-8579(19)30218-3.
  8. Bleasdale SC, Sikka MK, Moritz DC, Frizen-Pedicini C, Stiehl E, Brosseau LM, Jones RM; Experience of Chicagoland acute care hospitals in preparing for Ebola virus disease 2014-2015, Journal of Occupational and Environmental Hygiene, 2019 Jul; 16:8, 582-591. DOI: 10.1080/15459624.2019.1628966.
  9. Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA; Antibacterial Resistance Leadership Group. Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants, Antimicrobial Agents Chemother, 2018 Jul 27; 62 (8).
  10. Bunnell KL, Pai, MP, Sikka M, Bleasdale, S, Wenzler E, Danziger LH, Rodvold KA. Pharmacokinectics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III, Adult Subjects. Antimicrobial Agents and Chemotherapy, 2018, April, 62 (4) 1-12.
  11. Weaver FM, Trick WE, Evans CT, Lin MY, Adams W, Pho MT, Bleasdale SC, Mullane KM, Johnson S, Sikka MK, Peterson LR, Solomonides AE, Gerding DN. The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors. Infect Control Hosp Epidemiol. 2017 Sep 26:1-7. doi: 10.1017/ice.2017.208. PubMed PMID: 28946934.  
  12. Means L, Bleasdale S, Sikka M, Gross AE. Predictors of Hospital Readmission in Patients Receiving Outpatient Parenteral Antimicrobial Therapy. Pharmacotherapy. 2016 Aug;36(8):934-9. doi: 10.1002/phar.1799. Epub 2016 Jul 29. PubMed PMID: 27393717.
  13. Hayden MK, Lin MY, Lolans K, Weiner S, Blom D, Moore NM, Fogg L, Henry D, Lyles R, Thurlow C, Sikka M, Hines D, Weinstein RA;Centers for Disease Control and Prevention Epicenters Program.. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015 Apr 15;60(8):1153-61. doi: 10.1093/cid/ciu1173. Epub 2014 Dec 23. PubMed PMID: 25537877.
  14. Lyles RD, Moore NM, Weiner SB, Sikka M, Lin MY, Weinstein RA, Hayden MK, Sinkowitz-Cochran RL. Understanding staff perceptions about Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae control efforts in Chicago long-term acute care hospitals.Infect Control Hosp Epidemiol. 2014 Apr;35(4):367-74. doi: 10.1086/675596. PubMed PMID: 24602941.
  15. Chemaly RF, Rathod DB, Sikka MK, Hayden MK, Hutchins M, Horn T, Tarrand J, Adachi J, Nguyen K, Trenholme G, Raad I. Serratia marcescens bacteremia because of contaminated prefilled heparin and saline syringes: a multi-state report. Am J Infect Control. 2011 Aug;39(6):521-4. doi: 10.1016/j.ajic.2010.08.020. Epub 2011 Apr 13. PubMed PMID: 21492963.
  16. Sikka MK, Hayden MK, Pur S, Segreti J, Harris AA, Weinstein RA, Trenholme G. Microbiologic and clinical epidemiologic characteristics of the Chicago subset of a multistate outbreak of Serratia marcescens bacteremia. Infect Control Hosp Epidemiol. 2010 Nov;31(11):1191-3. doi: 10.1086/657074. PubMed PMID: 20923282.